Compare DexCom, Inc. (DXCM) vs Virgin Galactic Holdings, Inc. (SPCE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Virgin Galactic Holdings, Inc. — how do they compare? DexCom, Inc. trades at $84.38 (market cap $31.86B), while Virgin Galactic Holdings, Inc. trades at $2.97 (market cap $445.69M). The key difference: DexCom, Inc. is far larger — about 71.5× Virgin Galactic Holdings, Inc.'s market cap, and DexCom, Inc. is trading nearer its 52-week high, Virgin Galactic Holdings, Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold DexCom, Inc. for 62 Days and Virgin Galactic Holdings, Inc. for 69 Days on average.
| DXCM | SPCE | |
|---|---|---|
Market Cap | $31.86B | $445.69M |
Volume | 3,607,070 | 5,128,850 |
Sector | Health | Industrials |
52-Week High | $92.34 | $7.52 |
52-Week Low | $54.84 | $2.17 |
Typical Hold Time | 62 Days | 69 Days |
Enterprise Value | $31.32B | $409.68M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DXCM trades at $84.3, up 1.09% today, with a bearish technical signal but strong fundamentals. Revenue grew to $4.66B in 2025, with net income of $836.3M and a 17.93% margin. The stock has a P/E of 33.32 and P/S of 6.74. Recent news highlights growth in CGM adoption for Type 2 diabetes. Analyst consensus is bullish with an average price target of $95.07, supported by 42 buy ratings.
Outlook remains positive due to earnings beats and market expansion, but risks include competition and reimbursement challenges. The stock offers growth potential, yet investors should monitor execution against high valuations and technical resistance near $85.
Virgin Galactic (SPCE) trades at $3.01, down 1.95% on the day, reflecting persistent operational losses and a bearish technical outlook. The company continues to burn cash with negative gross and net profit margins, though recent earnings beats and strong ticket demand for future spaceflights offer a glimmer of hope. Cash flow trends show a gradual improvement, with a projected positive net cash flow of $25 million in 2026.
The outlook remains high-risk, high-reward. The path to profitability hinges on the successful commercial launch of Delta flights in 2027. While analyst sentiment is mixed and significant dilution and debt are concerns, the company's unique position in commercial spaceflight presents a speculative opportunity for investors with a long-term horizon and high risk tolerance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Virgin Galactic Holdings, Inc.
Virgin Galactic Holdings Inc. develops space vehicles. The Company designs exploration technology such as missiles, rockets, and other related equipment. Virgin Galactic Holdings serves customers in the United States.
Read more on SPCE →
